Nuevolution: Data from BET-inhibitor in cancer models

Research Note

2019-02-21

14:57

Nuevolution today announced the first pre-clinical data in cancer models from their BET-BD1 inhibitor, which has so far been focused on fibrotic and dermatological diseases.

MS

Mathias Spinnars

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.